HSP90 inhibitors: Targeting the cancer chaperone for combinatorial blockade of oncogenic pathways

Cancer Drug Design and Discovery

Volumn , Issue , 2008, Pages 305-335

  Sharp, Swee Y ^a   Jones, Kieth ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882527526     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369448-5.50016-1     Document Type: Chapter

References (192)

1. Agatsuma T., Ogawa H., Akasaka K., et al. Halohydrin and oxime derivatives of radicicol: synthesis and anti-tumor activities. Bioorg. Med. Chem. 2002, 10:3445-3454.
2. Ali M.M., Roe S.M., Vaughan C.K., et al. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 2006, 440:1013-1017.
3. Allan R.K., Mok D., Ward B.K., Ratajczak T Modulation of chaperone function and co-chaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281:7161-7171.
4. Altieri D.C., Marchisio P.C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 1999, 79:1327-1333.
5. Andrus M.B., Meredith E.L., Hicken E.J., et al. Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin: asymmetric glycolate aldol reactions and biological evaluation. J. Org. Chem. 2003, 68:8162-8169.
6. Aoyagi S., Archer T.K. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005, 15:565-567.
7. Argon Y., Simen B.B. GRP94, an ER chaperone with protein and peptide binding properties. Semin. Cell Dev. Biol. 1999, 10:495-505.
8. Atrash B., Cooper T.S., et al. Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol. Tetrahedron Lett. 2006, 47:2237-2240.
9. Bagatell R., Paine-Murrieta G.D., Taylor C.W., et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90binding agents. Clin. Cancer Res. 2000, 6:3312-3318.
10. Bali P., Pranpat M., Bradner J., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280:26,729-26,734.
11. Banerji U., O'Donnell A., Scurr M., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:4152-4161.
12. Banerji U., Walton M., Raynaud F., et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin. Cancer Res. 2005, 11:7023-7032.
13. Barnes J.A., Dix D.J., Collins B.W., et al. Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia. Cell Stress Chaperones. 2001, 6:316-325.
14. Barril X., Brough P., Drysdale M., et al. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:5187-5191.
15. Barril X., Beswick M.C., Collier A., et al. 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg. Med. Chem. Lett. 2006, 16:2543-2548.
16. Bauer S., Yu L., Read M., et al. IPI504, a novel HSP90 inhibitor, causes inhibition and degradation of KIT in imatinib-resistant GIST: Rationale for therapeutic targeting in GIST. Clin. Cancer Res. 2005, 11(24 Suppl.):S9111.
17. Beere H.M., Wolf B.B., Cain K., et al. Heatshock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. 2000, 2:469-475.
18. Biamonte M.A., Shi J., Hong K., et al. Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49:817-828.
19. Blank M., Mandel M., Keisari Y., et al. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 2003, 63:8241-8247.
20. Bukau B., Deuerling E., Pfund C., Craig E.A. Getting newly synthesized proteins into shape. Cell 2000, 101:119-122.
21. Burger A.M., Fiebig H.H., Stinson S.F., Sausville E.A. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004, 15:377-387.
22. Burlison J.A., Neckers L., Smith A.B., et al. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc. 2006, 128:15529-15536.
23. Caplan A.J., Mandal A.K., Theodoraki M.A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 2006, 17:87-92.
24. Chanan-Khan A., Richardson P., Alsina M., et al. Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). J. Clin. Oncol. (Meeting Abstracts) 2006, 24:3066.
25. Chant I.D., Rose P.E., Morris A.G. Analysis of heat-shock protein expression in myeloid leukemia cells by fl ow cytometry. Br. J. Haematol. 1995, 90:163-168.
26. Chen B., Piel W.H., Gui L., et al. The HSP90 family of genes in the human genome: Insights into their divergence and evolution. Genomics 2005, 86:627-637.
27. Chene P ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 2002, 1:665-673.
28. Cheung K.M., Matthews T.P., et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:3338-3343.
29. Chiosis G Targeting chaperones in transformed systems - a focus on Hsp90 and cancer. Expert Opin. Ther. Targets 2006, 10:37-50.
30. Chiosis G Discovery and development of purine-scaffold hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6:1183.
31. Chiosis G., Timaul M.N., Lucas B., et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8:289-299.
32. Chiosis G., Lucas B., Shtil A., et al. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10:3555-3564.
33. Chiosis G., Huezo H., Rosen N., et al. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol. Cancer Ther. 2003, 2:123-129.
34. Chiosis G., Caldas L.E., Solit D Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr. Opin. Invest. Drugs 2006, 7:534-541.
35. Chung Y.L., Troy H., Banerji U., et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst. 2003, 95:1624-1633.
36. Ciocca D.R., Clark G.M., Tandon A.K., et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J. Natl Cancer Inst. 1993, 85:570-574.
37. Clarke P.A., Hostein I., Banerji U., et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000, 19:4125-4133.
38. Collins I., Workman P New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006, 2:689-700.
39. Connell P., Ballinger C.A., Jiang J., et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 2001, 3:93-96.
40. Conroy S.E., Sasieni P.D., Fentiman I., Latchman D.S. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur. J. Cancer 1998, 34:942-943.
41. Cooper T.S., Atrash B., Sheldrake P., et al. Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. Tetrahedron Lett. 2006, 47:2241-2243.
42. Creagh E.M., Sheehan D., Cotter T.G. Heat shock proteins - modulators of apoptosis in tumor cells. Leukemia 2000, 14:1161-1173.
43. da Rocha Dias D.S., Friedlos F., Light Y., et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino17-demethoxygeldanamycin. Cancer Res. 2005, 65:10686-10691.
44. DeBoer C., Meulman P.A., Wnuk R.J., Peterson D.H. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo) 1970, 23:442-447.
45. Delmotte P., Delmotteplaquee J A new antifungal substance of fungal origin. Nature 1953, 171:344.
46. Demidenko Z.N., Vivo C., Halicka H.D., et al. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Diff. 2006, 13:1434-1441.
47. Dobson C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 1999, 24:329-332.
48. Dollins D.E., Immormino R.M., Gewirth D.T. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90. Basis for nucleotideinduced conformational change. J. Biol. Chem. 2005, 280:30438-30447.
49. Drysdale M., Dymock B., Barril X. Preparation of pyridothiophene compounds as Hsp90 inhibitors. WO 200534950 2005.
50. Dymock B.W., Barril X., Brough P.A., et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48:4212-4215.
51. Dymock B., Drysdale M., Fromont C., Jordan A. Preparation of pyrimidothiophenes as Hsp90 inhibitors. WO 200521552 2005.
52. Egorin M.J., Zuhowski E.G., Rosen D.M., et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol. 2001, 47:291-302.
53. Fang L., Battisti R.F., Cheng H., et al. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J. Med. Chem. 2006, 49:6290-6297.
54. Felts S.J., Owen B.A., Nguyen P., et al. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 2000, 275:3305-3312.
55. Fewell S.W., Smith C.M., Lyon M.A., et al. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J. Biol. Chem. 2004, 279:51,131-51,140.
56. Fortugno P., Beltrami E., Plescia J., et al. Regulation of survivin function by Hsp90. Proc. Natl Acad. Sci. USA 2003, 100:13,791-13,796.
57. Fuino L., Bali P., Wittmann S., et al. Histone deacetylase inhibitor LAQ824 down-regulates Her2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003, 2:971-984.
58. Garrido C., Schmitt E., Cande C., et al. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003, 2:579-584.
59. George P., Bali P., Annavarapu S., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
60. Grammatikakis N., Vultur A., Ramana C.V., et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J. Biol. Chem. 2002, 277:8312-8320.
61. Grbovic O.M., Basso A.D., Sawai A., et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA 2006, 103:57-62.
62. Guo W., Reigan P., Siegel D., et al. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005, 65:10,006-10,015.
63. Guo F., Rocha K., Bali P. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005, 65:10,536-10,544.
64. Gyurkocza B., Plescia J., Raskett C.M., et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl Cancer Inst. 2006, 98:1068-1077.
65. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
66. Hargreaves R., David C.L., Whitesell L., Skibo E.B. Design of quinolinedione-based geldanamycin analogues. Bioorg. Med. Chem. Lett. 2003, 13:3075-3078.
67. Hernandez M.P., Sullivan W.P., Toft D.O. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J. Biol. Chem. 2002, 277:38,294-38,304.
68. Hickey E., Brandon S.E., Smale G., et al. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol. Cell Biol. 1989, 9:2615-2626.
69. Hieronymus H., Lamb J., Ross K.N., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
70. Honma M., Stubbs M., Collins I., et al. Identification of novel keratinocyte differentiation modulating compounds by high-throughput screening. J. Biomol. Screen 2006, 11:977-984.
71. Hostein I., Robertson D., DiStefano F., et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001, 61:4003-4009.
72. Howes R., Barril X., Dymock B.W., et al. A fl uorescence polarization assay for inhibitors of Hsp90. Analyt. Biochem. 2006, 350:202-213.
73. Itoh H., Ogura M., Komatsuda A., et al. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 1999, 343(Pt 3):697-703.
74. Ivy P.S., Schoenfeldt M Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG. Oncology (Williston Park) 18, 610, 2004, 615:619-620.
75. Jaattela M., Pinola M., Saksela E Heat shock inhibits the cytotoxic action of TNF-alpha in tumor cells but does not alter its noncytotoxic actions in endothelial and adrenal cells. Lymphokine Cytokine Res. 1991, 10:119-125.
76. Jaattela M., Wissing D., Kokholm K., et al. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J, 1998, 17:6124-6134.
77. Janin Y.L. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 2005, 48:7503-7512.
78. Johnson J., Corbisier R., Stensgard B., Toft D The involvement of p23, hsp90, and immunophilins in the assembly of progesterone receptor complexes. J. Steroid Biochem. Mol. Biol. 1996, 56:31-37.
79. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl Cancer Inst. 2000, 92:1564-1572.
80. Kamal A., Thao L., Sensintaffar J., et al. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
81. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478:23-43.
82. Kawaguchi Y., Kovacs J.J., McLaurin A., et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
83. Kelland L.R., Sharp S.Y., Rogers P.M., et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 1999, 91:1940-1949.
84. Kimmins S., MacRae T.H. Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins. Cell Stress Chaperones 2000, 5:76-86.
85. Kimura E., Enns R.E., Alcaraz J., et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heatshock protein HSP-60. J. Clin. Oncol. 1993, 11:891-898.
86. Koishi M., Yokota S., Mae T., et al. The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo. Clin. Cancer Res. 2001, 7:215-219.
87. Kreusch A., Han S., Brinker A., et al. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 2005, 15:1475-1478.
88. Kristeleit R., Tandy D., Atadja P., et al. Effects of the histone deacetylase inhibitor (HDACi) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumors enrolled in a Phase I clinical trial. Proc. Am. Assoc. Clin. Oncol. 2004, 22:3032.
89. Kwon H.J., Yoshida M., Fukui Y., et al. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res. 1992, 52:6926-6930.
90. Langer T., Schlatter H., Fasold H Evidence that the novobiocin-sensitive ATP-binding site of the heat shock protein 90 (hsp90) is necessary for its autophosphorylation. Cell Biol. Intl 2002, 26:653-657.
91. le Brazidec J.Y., Kamal A., Busch D., et al. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. J. Med. Chem. 2004, 47:3865-3873.
92. Li C.Y., Lee J.S., Ko Y.G., et al. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J. Biol. Chem. 2000, 275:25,665-25,671.
93. Li S.M., Heide L New aminocoumarin antibiotics from genetically engineered Streptomyces strains. Curr. Med. Chem. 2005, 12:419-427.
94. Lindquist S., Craig E.A. The heat-shock proteins. Annu. Rev. Genet. 1988, 22:631-677.
95. Llauger L., He H., Kim J., et al. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48:2892-2905.
96. Maloney A., Workman P HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2:3-24.
97. Maloney A., Clarke P., Naaby-Hansen S., et al. Gene and protein expression profiling of human ovarian cancer cells treated with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Cancer Res. 2007, 67:3239-3253.
98. Marcu M.G., Chadli A., Bouhouche I., et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATPbinding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275:37,181-37,186.
99. Marcu M.G., Schulte T.W., Neckers L Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl Cancer Inst. 2000, 92:242-248.
100. Martinez-Ruiz A., Villanueva L., de Gonzalez O.C., et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc. Natl Acad. Sci. USA 2005, 102:8525-8530.
101. Matthews R.C., Burnie J.P. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004, 22:865-871.
102. Matthews R.C., Rigg G., Hodgetts S., et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 2003, 47:2208-2216.
103. McDaniel R., Welch M., Hutchinson C.R. Genetic approaches to polyketide antibiotics. 1. Chem. Rev. 2005, 105:543-558.
104. McDonald E., Jones K., Brough P.A., et al. Discovery and development of pyrazole-scaffold hsp90 inhibitors. Curr. Top. Med. Chem. 2006, 6:1193-1203.
105. McDonald E., Workman P., Jones K Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 2006, 6:1091-1107.
106. McMillan D.R., Xiao X., Shao L., et al. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heatinducible apoptosis. J. Biol. Chem. 1998, 273:7523-7528.
107. Meli M., Pennati M., Curto M., et al. Smallmolecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J. Med. Chem. 2006, 49:7721-7730.
108. Mimnaugh E.G., Xu W., Vos M., et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. 2004, 3:551-566.
109. Modi S., Stopeck A., Gordon M.S., et al. Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). J. Clin. Oncol. (Meeting Abstracts) 2006, 24:501.
110. Morimoto R.I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 1998, 12:3788-3796.
111. Moulin E., Zoete V., Barluenga S., et al. Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogs. J Am. Chem. Soc. 2005, 127:6999-7004.
112. Munster P.N., Basso A., Solit D., et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapyinduced apoptosis in an RB- and schedule-dependent manner 2001, See also: E.A. Sausville (2001). Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin. Cancer Res. 7, 2155-2158; 2228-2236.
113. Murphy P.J., Morishima Y., Kovacs J.J., et al. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 2005, 280:33,792-33,799.
114. Pacey S., Banerji U., Judson I., Workman P. Hsp90 inhibitors in the clinic. Handbook Exper. Pharmacol 2006, 331-358.
115. Panaretou B., Siligardi G., Meyer P., et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 2002, 10:1307-1318.
116. Patel K., Piagentini M., Rascher A., et al. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem. Biol. 2004, 11:1625-1633.
117. Pearl L.H., Prodromou C Structure and mechanism of the hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
118. Picard D Chaperoning steroid hormone action. Trends Endocrinol. Metab. 2006, 17:229-235.
119. Plescia J., Salz W., Xia F., et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7:457-468.
120. Polla B.S., Kantengwa S., Francois D., et al. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury. Proc. Natl Acad. Sci. USA 1996, 93:6458-6463.
121. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exper. Biol. Med. (Maywood) 2003, 228:111-133.
122. Prodromou C., Roe S.M., O'Brien R., et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90:65-75.
123. Prodromou C., Panaretou B., Chohan S., et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J. 2000, 19:4383-4392.
124. Proisy N., Sharp S.Y., Boxall K., et al. Inhibition of hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. Chem. Biol. 2006, 13:1203-1215.
125. Radford S.E. Protein folding: progress made and promises ahead. Trends Biochem. Sci. 2000, 25:611-618.
126. Ralhan R., Kaur J Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin. Cancer Res. 1995, 1:1217-1222.
127. Rastelli G., Tian Z.Q., Wang Z., et al. Structurebased design of 7-carbamate analogs of geldanamycin. Bioorg. Med. Chem. Lett. 2005, 15:5016-5021.
128. Richter K., Buchner J hsp90: twist and fold. Cell 2006, 127:251-253.
129. Ritossa F A new puffing pattern induced by temperature shock and DNP in Drosophila. Experienta 1962, 18:571-573.
130. Roe S.M., Prodromou C., O'Brien R., et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42:260-266.
131. Rosenhagen M.C., Soti C., Schmidt U., et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol. Endocrinol. 2003, 17:1991-2001.
132. Rowlands M.G., Newbatt Y.M., Prodromou C., et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Analyt. Biochem. 2004, 327:176-183.
133. Rutherford S.L., Lindquist S Hsp90 as a capacitor for morphological evolution. Nature 1998, 396:336-342.
134. Sain N., Krishnan B., Ormerod M.G., et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 2006, 5:1197-1208.
135. Saleh A., Srinivasula S.M., Balkir L., et al. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol. 2000, 2:476-483.
136. Salehi A.H., Morris S.J., Ho W.C., et al. AEG3482 is an antiapoptotic compound that inhibits Jun kinase activity and cell death through induced expression of heat shock protein 70. Chem. Biol. 2006, 13:213-223.
137. Sanderson S., Valenti M., Gowan S., et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol. Cancer Ther. 2006, 5:522-532.
138. Sasaki K., Rinehart K.L., Slomp G., et al. Geldanamycin. I. Structure assignment. J. Am. Chem Soc. 1970, 92:7591-7593.
139. Schnur R.C., Corman M.L., Gallaschun R.J., et al. erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J. Med. Chem. 1995, 38:3813-3820.
140. Schnur R.C., Corman M.L., Gallaschun R.J., et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 1995, 38:3806-3812.
141. Scholz G.M., Cartledge K., Hall N.E. Identification and characterization of Harc, a novel Hsp90-associating relative of Cdc37. J. Biol. Chem. 2001, 276:30,971-30,979.
142. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42:273-279.
143. Schulte T.W., An W.G., Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 1997, 239:655-659.
144. Schulte T.W., Akinaga S., Soga S., et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3:100-108.
145. Scroggins B.T., Robzyk K., Wang D., et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 2007, 25:151-159.
146. Sharp S.Y., Boxall K., Rowlands M., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res. 2007, 67:2206-2216.
147. Shen G., Blagg B.S. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org. Lett. 2005, 7:2157-2160.
148. Shen G., Yu X.M., Blagg B.S. Syntheses of photolabile novobiocin analogues. Bioorg. Med. Chem. Lett. 2004, 14:5903-5906.
149. Shiotsu Y., Soga S., Akinaga S Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex. Leukemia Lymphoma 2002, 43:961-968.
150. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
151. Smith N., Hayes A., James K., et al. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol. Cancer Ther. 2006, 5:1628-1637.
152. Smith N., Raynaud F., Workman P The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery. Mol. Cancer Ther. 2007, 6:428-440.
153. Smith V., Sausville E.A., Camalier R.F., et al. Comparison of 17-dimethylaminoethylamino17-demethoxy-geldanamycin (17DMAG) and 17allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56:126-137.
154. Smith-Jones P.M., Solit D.B., Akhurst T., et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. 2004, 22:701-706.
155. Soga S., Shiotsu Y., Akinaga S., Sharma S.V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3:359-369.
156. Soldano K.L., Jivan A., Nicchitta C.V., Gewirth D.T. Structure of the N-terminal domain of GRP94: basis for ligand specificity and regulation. J. Biol. Chem. 2003, 48:48,330-48,338.
157. Solit D.B., Rosen N Hsp90: a novel target for cancer therapy. Curr. Top. Med. Chem. 2006, 6:1205-1214.
158. Solit D.B., Zheng F.F., Drobnjak M., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8:986-993.
159. Solit D.B., Basso A.D., Olshen A.B., et al. Inhibition of heat shock protein 90 function downregulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003, 63:2139-2144.
160. Soti C., Racz A., Csermely P A nucleotidedependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J. Biol. Chem. 2002, 277:7066-7075.
161. Stankiewicz A.R., Lachapelle G., Foo C.P., et al. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J. Biol. Chem. 2005, 280:38,729-38,739.
162. Supko J.G., Hickman R.L., Grever M.R., Malspeis L Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36:305-315.
163. Sydor J.R., Normant E., Pien C.S., et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anticancer agent directed against Hsp90. Proc. Natl Acad. Sci. USA 2006, 103:17,408-17,413.
164. Takayama S., Reed J.C. Molecular chaperone targeting and regulation by BAG family proteins. Nat. Cell Biol. 2001, 3:E237-E241.
165. Tanabe K., Tokumoto T., Ishikawa N., et al. Effect of deoxyspergualin on the long-term outcome of renal transplantation. Transplant Proc. 2000, 32:1745-1746.
166. Uehara Y Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets 2003, 3:325-330.
167. Vastag B HSP-90 inhibitors promise to complement cancer therapies. Nat. Biotechnol. 2006, 24:1307.
168. Vaughan C.K., Gohlke U., Sobott F., et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 2006, 23:697-707.
169. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19:286-293.
170. Vilenchik M., Solit D., Basso A., et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11:787-797.
171. Wang X., Venable J., LaPointe P., et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fi brosis. Cell 2006, 127:803-815.
172. Weinstein I.B., Joe A.K. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3:448-457.
173. Westerheide S.D., Kawahara T.L., Orton K., Morimoto R.I Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J. Biol. Chem. 2006, 281:9616-9622.
174. Whitesell L., Lindquist S.L HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
175. Whitesell L., Shifrin S.D., Schwab G., Neckers L.M. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992, 52:1721-1728.
176. Whitesell L., Mimnaugh E.G., de Costa B., et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. USA 1994, 91:8324-8328.
177. Workman P Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2003, 2:131-138.
178. Workman P Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003, 3:297-300.
179. Workman P Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206:149-157.
180. Workman P., Aboagye E.O., Chung Y.L., et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst. 2006, 98:580-598.
181. Wright L., Barril X., Dymock B., et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 11:775-785.
182. Yamamoto K., Garbaccio R.M., Stachel S.J., et al. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew. Chem. Intl Ed Engl. 2003, 42:1280-1284.
183. Yang H., Chen D., Cui Q.C., et al. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66:4758-4765.
184. Yin X., Zhang H., Burrows F., et al. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin. Cancer Res. 2005, 11:3889-3896.
185. Yokota S., Kitahara M., Nagata K Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000, 60:2942-2948.
186. Young J.C., Agashe V.R., Siegers K., Hartl F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 2004, 5:781-791.
187. Yu X.M., Shen G., Neckers L., et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 2005, 127:12,778-12,779.
188. Yufu Y., Nishimura J., Nawata H High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leukemia Res. 1992, 16:597-605.
189. Zhang H., Chung D., Yang Y.C., et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol. Cancer Ther. 2006, 5:1256-1264.
190. Zhao J.F., Nakano H., Sharma S Suppression of RAS and MOS transformation by radicicol. Oncogene 1995, 11:161-173.
191. Zhao R., Davey M., Hsu Y.C., et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120:715-727.
192. Zou J., Guo Y., Guettouche T., et al. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stresssensitive complex with HSF1. Cell 1998, 94:471-480.